EA201400568A1 - Альбуминсвязывающие антитела и их связывающие фрагменты - Google Patents
Альбуминсвязывающие антитела и их связывающие фрагментыInfo
- Publication number
- EA201400568A1 EA201400568A1 EA201400568A EA201400568A EA201400568A1 EA 201400568 A1 EA201400568 A1 EA 201400568A1 EA 201400568 A EA201400568 A EA 201400568A EA 201400568 A EA201400568 A EA 201400568A EA 201400568 A1 EA201400568 A1 EA 201400568A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seq
- variable domain
- antibodies
- fragments
- application
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 4
- 102000009027 Albumins Human genes 0.000 title 1
- 108010088751 Albumins Proteins 0.000 title 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Abstract
В заявке описано связывающее сывороточный альбумин антитело или его фрагмент, содержащее/содержащий вариабельный домен тяжелой цепи, который имеет последовательность, представленную в SEQ ID NO: 1 или SEQ ID NO: 2, и/или содержащее/содержащий вариабельный домен легкой цепи, который имеет последовательность, представленную в SEQ ID NO: 3 или SEQ ID NO: 4, в частности, содержащее/содержащий вариабельный домен тяжелой цепи и вариабельный домен легкой цепи, которые имеют последовательности, представленные в SEQ ID NO: 1 и SEQ ID NO: 3, или вариабельный домен тяжелой цепи и вариабельный домен легкой цепи, которые имеют последовательности, представленные в SEQ ID NO: 2 и SEQ ID NO: 4. В заявке описаны также полинуклеотиды, кодирующие антитела или фрагменты, векторы, которые их содержат, и клетки-хозяева, обладающие способностью экспрессировать полинуклеотиды. В заявке описаны также фармацевтические композиции, содержащие антитела или фрагменты, и терапевтическое применение любого из них.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558559P | 2011-11-11 | 2011-11-11 | |
| PCT/EP2012/072335 WO2013068571A1 (en) | 2011-11-11 | 2012-11-09 | Albumin binding antibodies and binding fragments thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201400568A1 true EA201400568A1 (ru) | 2014-12-30 |
| EA033766B1 EA033766B1 (ru) | 2019-11-22 |
Family
ID=47358092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201400568A EA033766B1 (ru) | 2011-11-11 | 2012-11-09 | Альбуминсвязывающие антитела и их связывающие фрагменты |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9803004B2 (ru) |
| EP (1) | EP2776466B1 (ru) |
| JP (1) | JP6411214B2 (ru) |
| KR (1) | KR102048382B1 (ru) |
| CN (1) | CN103946237B (ru) |
| AU (1) | AU2012335496B2 (ru) |
| BR (1) | BR112014011304B1 (ru) |
| CA (1) | CA2856216C (ru) |
| CY (1) | CY1119647T1 (ru) |
| DK (1) | DK2776466T3 (ru) |
| EA (1) | EA033766B1 (ru) |
| ES (1) | ES2649098T3 (ru) |
| HR (1) | HRP20171608T1 (ru) |
| HU (1) | HUE037142T2 (ru) |
| IL (1) | IL232226B (ru) |
| IN (1) | IN2014DN03451A (ru) |
| LT (1) | LT2776466T (ru) |
| MX (1) | MX351502B (ru) |
| NO (1) | NO2839445T3 (ru) |
| PL (1) | PL2776466T3 (ru) |
| PT (1) | PT2776466T (ru) |
| SG (1) | SG11201401649VA (ru) |
| SI (1) | SI2776466T1 (ru) |
| WO (1) | WO2013068571A1 (ru) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112203C2 (uk) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| DK3039038T3 (da) * | 2013-08-30 | 2021-02-08 | Aprilbio Co Ltd | Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil |
| GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
| GB201508180D0 (en) * | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| CN107849104B (zh) | 2015-07-06 | 2021-08-27 | Ucb生物制药有限责任公司 | Tau结合抗体 |
| WO2017060242A1 (en) | 2015-10-05 | 2017-04-13 | Ucb Biopharma Sprl | Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| GB201602938D0 (en) | 2016-02-19 | 2016-04-06 | Ucb Biopharma Sprl | Protein purification |
| CA3022494A1 (en) * | 2016-05-01 | 2017-11-09 | Ucb Biopharma Sprl | Affinity engineered serum protein carrier binding domain |
| GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| EP3583125B1 (en) * | 2017-02-16 | 2025-01-22 | Sonnet BioTherapeutics, Inc. | Albumin binding domain fusion proteins |
| ES3015094T3 (en) * | 2017-06-05 | 2025-04-29 | Numab Therapeutics AG | Anti-hsa antibodies |
| WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| GB201711481D0 (en) | 2017-07-17 | 2017-08-30 | Ucb Biopharma Sprl | Protein purification |
| KR102204315B1 (ko) * | 2018-11-16 | 2021-01-18 | 한국세라믹기술원 | 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도 |
| JP7581315B2 (ja) | 2019-08-02 | 2024-11-12 | ユーシービー バイオファルマ エスアールエル | 抗体を精製するための方法 |
| CN112409480B (zh) * | 2019-08-20 | 2024-08-27 | 四川科伦博泰生物医药股份有限公司 | 结合血清白蛋白的蛋白及其用途 |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| CN115667298A (zh) | 2020-03-27 | 2023-01-31 | Ucb生物制药有限责任公司 | 自主凸起结构域肽 |
| KR102367488B1 (ko) * | 2020-06-29 | 2022-02-25 | 주식회사 프로테인웍스 | 단일사슬항체-알부민 약물 복합체의 분석방법 |
| MX2023004436A (es) | 2020-10-15 | 2023-05-08 | UCB Biopharma SRL | Moleculas de union que multimerizan cd45. |
| IL303295A (en) | 2020-12-07 | 2023-07-01 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| AR124250A1 (es) | 2020-12-07 | 2023-03-01 | UCB Biopharma SRL | Anticuerpos |
| CN115181751A (zh) * | 2021-04-02 | 2022-10-14 | 苏州博腾生物制药有限公司 | 靶向白蛋白的嵌合抗原受体及其使用方法 |
| US20240254224A1 (en) | 2021-05-03 | 2024-08-01 | UCB Biopharma SRL | Antibodies |
| WO2022257868A1 (zh) * | 2021-06-07 | 2022-12-15 | 上海济煜医药科技有限公司 | 抗人血清白蛋白的抗原结合蛋白 |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| AR129610A1 (es) | 2022-06-15 | 2024-09-11 | UCB Biopharma SRL | Proteínas de fusión |
| CN119654337A (zh) | 2022-06-15 | 2025-03-18 | Ucb生物制药有限责任公司 | 用于预防、治疗或改善肾脏疾病的融合蛋白 |
| GB202318820D0 (en) | 2023-12-08 | 2024-01-24 | UCB Biopharma SRL | Antibodies |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ． | 新規な結合タンパク質の生成と選択 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| US5658727A (en) | 1991-04-10 | 1997-08-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| AU696293B2 (en) | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
| AU1736495A (en) | 1994-01-31 | 1995-08-15 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| DE19653722C2 (de) | 1996-12-10 | 2000-06-29 | Brose Fahrzeugteile | Beidseitig wirkende Verstellvorrichtung |
| NZ511956A (en) | 1997-02-21 | 2002-11-26 | Genentech Inc | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| DE69922159T2 (de) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Mehrzweck-antikörperderivate |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| ATE337403T1 (de) | 1999-12-24 | 2006-09-15 | Genentech Inc | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| AU2003245664A1 (en) | 2002-06-21 | 2004-01-06 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP2135879A3 (en) | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| EP1570267B1 (en) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| AU2005250216B2 (en) | 2004-06-01 | 2009-12-10 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| AU2005311098B2 (en) | 2004-12-01 | 2011-08-11 | Allergan, Inc. | Non-cytotoxic protein conjugates |
| GB0506912D0 (en) | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
| CN104004088B (zh) * | 2007-09-26 | 2017-11-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| HUE042114T2 (hu) * | 2009-02-17 | 2019-06-28 | Ucb Biopharma Sprl | Humán OX40-re specifikus ellenanyag-molekulák |
| CN102574914A (zh) * | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| US20120283415A1 (en) * | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
-
2012
- 2012-11-09 CA CA2856216A patent/CA2856216C/en active Active
- 2012-11-09 EA EA201400568A patent/EA033766B1/ru not_active IP Right Cessation
- 2012-11-09 IN IN3451DEN2014 patent/IN2014DN03451A/en unknown
- 2012-11-09 HU HUE12801467A patent/HUE037142T2/hu unknown
- 2012-11-09 BR BR112014011304-1A patent/BR112014011304B1/pt active IP Right Grant
- 2012-11-09 CN CN201280055064.0A patent/CN103946237B/zh active Active
- 2012-11-09 ES ES12801467.7T patent/ES2649098T3/es active Active
- 2012-11-09 US US14/356,181 patent/US9803004B2/en active Active
- 2012-11-09 HR HRP20171608TT patent/HRP20171608T1/hr unknown
- 2012-11-09 PL PL12801467T patent/PL2776466T3/pl unknown
- 2012-11-09 JP JP2014540494A patent/JP6411214B2/ja active Active
- 2012-11-09 DK DK12801467.7T patent/DK2776466T3/da active
- 2012-11-09 PT PT128014677T patent/PT2776466T/pt unknown
- 2012-11-09 WO PCT/EP2012/072335 patent/WO2013068571A1/en active Application Filing
- 2012-11-09 MX MX2014005546A patent/MX351502B/es active IP Right Grant
- 2012-11-09 LT LTEP12801467.7T patent/LT2776466T/lt unknown
- 2012-11-09 EP EP12801467.7A patent/EP2776466B1/en active Active
- 2012-11-09 SG SG11201401649VA patent/SG11201401649VA/en unknown
- 2012-11-09 KR KR1020147015678A patent/KR102048382B1/ko active Active
- 2012-11-09 AU AU2012335496A patent/AU2012335496B2/en active Active
- 2012-11-09 SI SI201231119T patent/SI2776466T1/sl unknown
-
2013
- 2013-04-12 NO NO13716781A patent/NO2839445T3/no unknown
-
2014
- 2014-04-24 IL IL23222614A patent/IL232226B/en active IP Right Grant
-
2017
- 2017-10-27 US US15/795,874 patent/US10023631B2/en active Active
- 2017-11-22 CY CY20171101222T patent/CY1119647T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| UA106607C2 (uk) | Білки специфічного зв'язування і їх застосування | |
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
| EA201491494A1 (ru) | Нацеливание на гликаны хондроитинсульфаты | |
| EA201491524A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
| MX2013002323A (es) | Anticuerpos para metaloproteinasa. | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| EA201491214A1 (ru) | Композиции и способы применения антител, нацеленных на фактор p | |
| PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| EA201291065A1 (ru) | Антитела против vla-4 | |
| MX388698B (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| WO2012091564A3 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |